Pacira BioSciences Inc(PCRX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 27 at 4:01 PM ET (Korea 10/28 05:01)
Full metrics table
| Index | RUT | P/E | 104.9 | EPS (ttm) | 0.35 | Insider Own | 3.75% | Shs Outstand | 39.8M | Perf Week | 0.05% |
| Market Cap | 1.45B | Forward P/E | 10.52 | EPS next Y | 19.44% | Insider Trans | -1.67% | Shs Float | 38.4M | Perf Month | 43.36% |
| Enterprise Value | 1.61B | PEG | 0.52 | EPS next Q | 0.73 | Inst Own | 105.75% | Short Float | 11.1% | Perf Quarter | 37.88% |
| Income | 0.01B | P/S | 1.94 | EPS this Y | 9.28% | Inst Trans | -8.68% | Short Ratio | 3.45 | Perf Half Y | 43.25% |
| Sales | 0.75B | P/B | 2.16 | EPS next 5Y | 20.25% | ROA | 1.05% | Short Interest | 4.26M | Perf YTD | 40.65% |
| Book/sh | 16.87 | P/C | 5.78 | EPS past 3/5Y | -22.97% -45.77% | ROE | 2.05% | 52W High | -0.72% ($36.67) | Perf Year | 70.65% |
| Cash/sh | 6.3 | P/FCF | 8.08 | Sales past 3/5Y | 2.89% 11.07% | ROIC | 1.36% | 52W Low | 93.62% ($18.80) | Perf 3Y | 32.03% |
| Dividend Est. | - | EV/EBITDA | 14.29 | EPS Y/Y TTM | 112.73% | Gross Margin | 71.53% | Volatility(W/M) | 0.23% 1.41% | Perf 5Y | -29.54% |
| Dividend TTM | - | EV/Sales | 2.16 | Sales Y/Y TTM | 5.71% | Oper. Margin | 3.7% | ATR (14) | 0.66 | Perf 10Y | 5.81% |
| Dividend Ex-Date | - | Quick Ratio | 3.94 | EPS Q/Q | 208.35% | Profit Margin | 1.96% | RSI (14) | 83.36 | Recom | 3 |
| Dividend Gr. 3/5Y | - | Current Ratio | 5.04 | Sales Q/Q | 6.24% | SMA20 | 10.42% ($32.97) | Beta | 0.27 | Target Price | $34.79 |
| Payout | - | Debt/Eq | 0.61 | Earnings | 2026/8/4 | SMA50 | 28.51% ($28.32) | Rel Volume | 0.38 | Prev Close | $36.38 |
| Employees | 829 | LT Debt/Eq | 0.6 | EPS/Sales Surpr. | 12.95% 0.7% | SMA200 | 47.79% ($24.63) | Avg Volume(3M) | 1.24M | Price | $36.4 |
| IPO | 2011/2/3 | Option/Short | Yes/Yes | Trades | 4381 | Volume | 471,814 | Change | 0.05% |
💉 Pacira BioSciences (PCRX) is a US specialty pharmaceutical company focused on non-opioid pain management. Its flagship product is EXPAREL, a post-surgical pain relief injection, and the company also operates ZILRETTA, a treatment for knee osteoarthritis, and the iovera system, a cryoanalgesia (cold-based nerve-blocking) device, giving it a product lineup that targets the full range of neuropathic pain pathways.
Over the past 1 year, on the higher side
1% below its 1-year high.
Traded less than usual. That is 38% of its average volume.
PCRX earns at a steady pace
Of every $100 in sales, $3.70 is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +9.3% this year.
Tap to view numbers
The price is about the industry average
Counting its debt, for $100 of yearly operating cash you would pay $1,429. Peers typically go for $1,429. Compared with its own 4-year average, it is 45% pricier now.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -29.5%. The S&P 500 did +70% over the same period.
Tap to view numbers
No dividend
It reinvests profits in the business instead of paying dividends.
Ownership is about average
Institutions hold 105.8%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #31 of 83 in the industry
Based on market cap of $1B.
ANIP#28 ANI Pharmaceuticals Inc $2B PER 15.3 
PAHC#29 Phibro Animal Health Corp $2B PER 15.8 
ETON#30 Eton Pharmaceuticals Inc $1B PER 135.3 PCRX#31 Pacira BioSciences Inc $1B PER 104.9 
CRON#32 Cronos Group Inc $1B PER 18.4 
FAQ
What kind of company is PCRX?
PCRX belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of PCRX?
The market cap of PCRX is approximately $1.5B, ranking 2,319 within its sector.
What is the P/E ratio of PCRX?
PCRX has a P/E ratio of approximately 104.9x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for PCRX?
PCRX has recorded a 52-week high of $36.67 and a low of $18.80.
